title: Updates on pathogen inactivation of plasma using Theraflex methylene blue system.
abstract: Methylene blue (MB) treated plasma has been in clinical use for 15 years. The current Theraflex MB-Plasma system has a number of improved features compared with the original Springe methodology. This article gives an overview of processing methodology and recent developments, pathogen inactivation capacity, pharmacokinetics and toxicology, effects on plasma proteins and storage stability, clinical experience and future perspectives. Emphasises will be placed on most recent literature and updated information available.
authors.affiliation: Blood Components Technology and Haemostasis/Thrombosis Consultancy, 50 Primrose Hill Road, London, UK. jseghatchian@btopenworld.com
authors.forename: Jerard
authors.initials: J
authors.lastname: Seghatchian
authors.forename: Wolfram H
authors.initials: WH
authors.lastname: Walker
authors.forename: Stefan
authors.initials: S
authors.lastname: Reichenberg
mesh_terms: D001798:Blood Proteins / Q000737:chemistry; D004203:Disinfection / Q000295:instrumentation* / Q000379:methods*; D006801:Humans; D008751:Methylene Blue / Q000737:chemistry*; D010949:Plasma; D055550:Protein Stability; D012449:Safety
chemical_list: D001798:Blood Proteins; D008751:Methylene Blue